Novavax, a US biotech company, said on Monday it would start phase II B clinical trials in South Africa to assess the effectiveness of its candidate vaccine, nvx-cov2373. “Novel coronavirus pneumonia is experiencing a sharp increase in winter in the past two years, and this important phase B clinical trial is likely to provide early indications for efficacy, as well as additional safety and immunity data for NVX-CoV2373,” said Gregory Glenn, President of
Novavax. Novavax announced on Friday that it had reached an agreement with the British government that the UK would start a late trial of nvx-cov2373 from this quarter to assess the vaccination status of its residents. If successful, the company will provide 60 million doses of the vaccine to the British government.